Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats HIV-1 infection. Sold as Kaletra, Lopinavir And Ritonavir. Every FDA application for this active ingredient: 4 branded and 10 generic.
As of Nov 15, 2026, FDA lists 14 applications for Lopinavir; Ritonavir (sold as Kaletra, Lopinavir And Ritonavir), first approved Sep 15, 2000, with 24 new uses approved and 0 published complete response letters.
First approved: Sep 15, 2000
Applications: 14
New uses approved: 24
Complete response letters: 0
Medicare spending, 2025: $3.0M
First approved in the EU: Mar 19, 2001
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Lopinavir-Ritonavir
Part D
$2.7M
-18%
516
Kaletra
Part D
$292K
-1%
44
Approvals in the EU (EMA)
First approved in the EU 6 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Abbvie
Mylan Labs Ltd